AR112217A1 - A COMBINATION OF AN INHIBITOR OF MPS1 AND A COMPOUND TAXAN, USES AND PHARMACEUTICAL COMPOSITIONS OF THE latter - Google Patents
A COMBINATION OF AN INHIBITOR OF MPS1 AND A COMPOUND TAXAN, USES AND PHARMACEUTICAL COMPOSITIONS OF THE latterInfo
- Publication number
- AR112217A1 AR112217A1 ARP180101809A AR112217A1 AR 112217 A1 AR112217 A1 AR 112217A1 AR P180101809 A ARP180101809 A AR P180101809A AR 112217 A1 AR112217 A1 AR 112217A1
- Authority
- AR
- Argentina
- Prior art keywords
- combination
- mps1
- inhibitor
- compound
- taxan
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
Abstract
Una combinación que comprende un inhibidor de MPS1 de fórmula (1) o una de sus sales de adición con un ácido o base farmacéuticamente aceptable, y un compuesto taxano, y composiciones y usos de esta.A combination comprising an MPS1 inhibitor of formula (1) or an addition salts thereof with a pharmaceutically acceptable acid or base, and a taxane compound, and compositions and uses thereof.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP17305847 | 2017-06-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR112217A1 true AR112217A1 (en) | 2019-10-02 |
Family
ID=59313173
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP180101809 AR112217A1 (en) | 2017-06-30 | 2018-06-29 | A COMBINATION OF AN INHIBITOR OF MPS1 AND A COMPOUND TAXAN, USES AND PHARMACEUTICAL COMPOSITIONS OF THE latter |
Country Status (2)
Country | Link |
---|---|
AR (1) | AR112217A1 (en) |
WO (1) | WO2019002542A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023113477A1 (en) * | 2021-12-15 | 2023-06-22 | Sillajen, Inc. | Pharmaceutical combinations for use in the treatment of neoplastic diseases |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA020703B9 (en) * | 2008-06-26 | 2015-12-30 | Ле Лаборатуар Сервье | Pyrazolo-quinazolines |
TW201437211A (en) * | 2013-03-01 | 2014-10-01 | Bayer Pharma AG | Substituted imidazopyridazines |
-
2018
- 2018-06-29 AR ARP180101809 patent/AR112217A1/en unknown
- 2018-06-29 WO PCT/EP2018/067572 patent/WO2019002542A1/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
WO2019002542A1 (en) | 2019-01-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2018002410A1 (en) | Mcl-1 inhibitors and methods of use thereof | |
CO2022001590A2 (en) | parp1 inhibitors | |
UY36151A (en) | ? A PHARMACEUTICAL COMPOSITION THAT INCLUDES A 3-QUINASA DELTA PHOSFOINOSYTIDE INHIBITOR AND A CORTICOSTEROID ?. | |
ECSP20025899A (en) | COMPOUNDS USEFUL TO INHIBIT CDK7 | |
AR107864A1 (en) | ACID 7a, 11b-DIHIDROXI-6a-ETIL-5b-COLAN-24-OICO AND PHARMACEUTICAL COMPOSITIONS | |
AR102981A1 (en) | INHIBITORS OF CELL NECROSIS AND METHODS OF PREPARATION OF THE SAME | |
NI201900077A (en) | JAK1 SELECTIVE INHIBITORS | |
CY1126067T1 (en) | FUSIONED PYROLINES THAT ACT AS UBIQUITIN-SPECIFIC PROTEASE 30 (USP30) INHIBITORS | |
CL2019001337A1 (en) | Pharmaceutical formulations. | |
UY37560A (en) | COMBINATION OF AN MCL-1 INHIBITOR AND A TAXAN COMPOUND, USES AND PHARMACEUTICAL COMPOSITIONS OF THIS | |
UY37941A (en) | DERIVATIVES OF BENCIMIDAZOL AND ITS USES | |
UY37342A (en) | COMBINATION OF A BCL-2 INHIBITOR AND AN MCL1 INHIBITOR, USES AND PHARMACEUTICAL COMPOSITIONS OF THESE | |
CO2022001814A2 (en) | Macrocyclic compounds as sting agonists and methods and uses thereof | |
DOP2019000015A (en) | COMBINATION OF A BCL-2 INHIBITOR AND AN MCL1 INHIBITOR, USES AND PHARMACEUTICAL COMPOSITIONS OF THESE | |
AR112217A1 (en) | A COMBINATION OF AN INHIBITOR OF MPS1 AND A COMPOUND TAXAN, USES AND PHARMACEUTICAL COMPOSITIONS OF THE latter | |
EA201990313A1 (en) | DERIVATIVE TRIAZOLOPYRAZINONE USED AS A HUMAN PDE1 INHIBITOR | |
AR106958A1 (en) | USEFUL TETRAHYDROTRIAZOLOPIRIMIDINE DERIVATIVES AS HNE INHIBITORS | |
AR107163A1 (en) | QUINASE INHIBITORS | |
CL2019001859A1 (en) | Combination of an mcl-1 inhibitor and a taxane compound, uses and pharmaceutical compositions thereof. | |
CY1119482T1 (en) | IMIDAZOLCARVOXAMIDES AND USE THESE FAAH INHIBITORS | |
CY1124177T1 (en) | COMPOUNDS USEFUL FOR INHIBITING ROR-GAMMA-T | |
CL2019001046A1 (en) | Combination therapy that includes an mdm2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancer. (divisional application 201601131) | |
AR113817A1 (en) | COMPOUNDS USEFUL TO INHIBIT CDK7 | |
EA201991623A1 (en) | COMBINATION MCL-1 INHIBITOR AND TAXANIC COMPOUND, THEIR APPLICATION AND PHARMACEUTICAL COMPOSITIONS | |
EA202090930A1 (en) | COMPOUNDS SUITABLE FOR CDK7 INHIBITION |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |